Emodepside Emodepside Emodepside
System Organ Class Placebo N=6 n (%) LSF 5 mg OD N=6 n (%)a LSF 10 mg OD N=6 n (%) LSF 10 mg BID N=6 n (%) All subjects N=24 n (%)
Any TEAE 4 (66.7) 5 (83.3) 6 (100.0) 6 (100) 21 (87.5)
Infections & infestations 0 4 (66.7) 4 (66.7) 1 (16.7) 9 (37.5)
Eye disorders 1 (16.7) 3 (50.0) 1 (16.7) 3 (50.0) 8 (33.3)
Musculoskeletal and connective tissue disorders 0 2 (33.3) 2 (33.3) 1 (16.7) 5 (20.8)
Nervous system disorders 2 (33.3) 2 (33.3) 0 0 4 (16.7)
Gastrointestinal disorders 2 (33.3) 2 (33.3) 0 0 4 (16.7)
General disorders and administration site disorders 1 (16.7) 1 (16.7) 1 (16.7) 1 (16.7) 4 (16.7)
Psychiatric disorders 0 2 (33.3) 1 (16.7) 0 3 (12.5)
Skin and subcutaneous tissue disorders 0 1 (16.7) 1 (16.7) 0 2 (8.3)
Investigations 0 0 0 1 (16.7) 1 (4.2)
Immune system disorders 0 0 0 1 (16.7) 1 (4.2)
Injury, poisoning and procedural complications 0 0 0 1 (16.7) 1 (4.2)
Metabolism and nutrition disorders 0 0 1 (16.7) 0 1 (4.2)
Respiratory, thoracic and mediastinal disorders 0 1 (16.7) 0 0 1 (4.2)
Surgical and medicinal procedures 0 0 1 (16.7) 0 1 (4.2)